SCM
SYRE icon

Suvretta Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Suvretta Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-107,310
Closed -$2.52M – 110
2024
Q2 		$2.52M Sell
107,310
-55,085
-34% -$1.86M 0.09% 67
2024
Q1 		$6.16M Hold
162,395
– – 0.23% 62
2023
Q4 		$3.49M Hold
162,395
– – 0.16% 60
2023
Q3 		$1.99M Sell
162,395
-1
-0% -$13 0.11% 65
2023
Q2 		$1.83M Hold
162,396
– – 0.1% 76
2023
Q1 		$1.18M Hold
162,396
– – 0.05% 78
2022
Q4 		$1.83M Hold
162,396
– – 0.08% 67
2022
Q3 		$2.14M Hold
162,396
– – 0.09% 64
2022
Q2 		$2.05M Hold
162,396
– – 0.08% 78
2022
Q1 		$9.34M Buy
162,396
+59,556
+58% +$5M 0.29% 54
2021
Q4 		$12.2M Buy
102,840
+16,531
+19% +$2.61M 0.24% 58
2021
Q3 		$17.2M Buy
86,309
+2,545
+3% +$445K 0.29% 51
2021
Q2 		$14.6M Buy
83,764
+29,081
+53% +$5.28M 0.22% 69
2021
Q1 		$10.8M Buy
54,683
+24,333
+80% +$4.67M 0.16% 73
2020
Q4 		$5.97M Buy
30,350
+9,186
+43% +$1.9M 0.09% 71
2020
Q3 		$3.75M Buy
21,164
+16,447
+349% +$3.04M 0.07% 69
2020
Q2 		$1.09M Buy
+4,717
New +$898K 0.02% 78

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Suvretta Capital Management's SYRE Position: Q3 2024 in Review

Suvretta Capital Management sold out of Spyre Therapeutics (SYRE) in Q3 2024, closing a stake of 107,310 shares — an estimated $2.52M sold.

Suvretta Capital Management first reported a position in SYRE in Q2 2020 and held it in 17 quarters. The position peaked at $17.2M in Q3 2021. 119 funds tracked by Wall St. Rank hold SYRE as of Q3 2024.

  • Suvretta Capital Management reported no remaining Spyre Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Suvretta Capital Management sold 107,310 Spyre Therapeutics shares in Q3 2024, an estimated $2.52M.
  • Suvretta Capital Management first reported a position in Spyre Therapeutics in Q2 2020 and held it in 17 quarters.
  • Suvretta Capital Management's Spyre Therapeutics position peaked at $17.2M in Q3 2021.
  • 119 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2024.

Based on Suvretta Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.